Evidence map›Paper›PMID 30642922›Full record

Trial reportAntimicrobial agents and chemotherapy2019

Stephanie Noviello, Sophie Magnet, Stephen Hawser, David B Huang

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephanie NovielloMotif BioSciences, Princeton, New Jersey, USA stephanie.noviello@motifbio.com.
Sophie MagnetIHMA Europe Sàrl, Monthey, Switzerland.
Stephen HawserIHMA Europe Sàrl, Monthey, Switzerland.
David B HuangMotif BioSciences, Princeton, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1 and -2). Seven hundred ninety baseline isolates, including

Indexed as

Anti-Bacterial AgentsDouble-Blind MethodHumansMethicillinMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPyrimidinesSkinSkin Diseases, BacterialStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial AgentsiclaprimMethicillinPyrimidinesGram-positive bacteriaiclaprimin vitro activityskin infections

Identifiers

PMID30642922
PMCPMC6437503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.